Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -12.50% is 55% above its 5-year average of -27.65%, near the high end of its 5-year range (-32.80%–-12.50%).
47.91% above its 12-month average of -23.99%.
Reported quarterly return on assets; no daily interpolation. Q1 FY2027 (2026-06-30): -1.82%.
RETURN ON ASSETS (ROA)
-12.50%
RETURN ON ASSETS (ROA) AVG TTM
-23.99%
RETURN ON ASSETS (ROA) AVG 3Y
-28.13%
RETURN ON ASSETS (ROA) AVG 5Y
-27.65%
RETURN ON ASSETS (ROA) AVG 10Y
-34.73%
RETURN ON ASSETS (ROA) AVG 15Y
-40.44%
RETURN ON ASSETS (ROA) AVG 20Y
-46.69%
CURRENT VS TTM AVG
+47.91%
CURRENT VS 3Y AVG
+55.57%
CURRENT VS 5Y AVG
+54.79%
CURRENT VS 10Y AVG
+64.01%
CURRENT VS 15Y AVG
+69.09%
CURRENT VS 20Y AVG
+73.23%
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+61.23%
vs the sector median at left
Sonoma Pharmaceuticals, Inc.
Market Cap
$5.79M
Return on Assets (ROA)
-12.50%
TTM Avg
-23.99%
3Y Avg
-28.13%
5Y Avg
-27.65%
Market Cap
$5.86M
Return on Assets (ROA)
-102.86%
TTM Avg
-76.90%
3Y Avg
-95.53%
5Y Avg
-184.55%
Market Cap
$5.70M
Return on Assets (ROA)
-69.39%
TTM Avg
-57.20%
3Y Avg
-55.49%
5Y Avg
-56.22%
Market Cap
$5.94M
Return on Assets (ROA)
-43.26%
TTM Avg
-20.33%
3Y Avg
-69.16%
5Y Avg
-65.79%
Market Cap
$5.89M
Return on Assets (ROA)
-81.62%
TTM Avg
-81.33%
3Y Avg
-106.24%
5Y Avg
-102.80%
Market Cap
$5.89M
Return on Assets (ROA)
83.82%
TTM Avg
-0.56%
3Y Avg
-31.49%
5Y Avg
-28.41%
Market Cap
$5.58M
Return on Assets (ROA)
-54.95%
TTM Avg
-72.19%
3Y Avg
-72.80%
5Y Avg
-69.14%
Market Cap
$5.59M
Return on Assets (ROA)
-68.33%
TTM Avg
-234.58%
3Y Avg
-196.81%
5Y Avg
-171.01%
Market Cap
$5.34M
Return on Assets (ROA)
-97.52%
TTM Avg
-106.09%
3Y Avg
-92.87%
5Y Avg
-84.52%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sonoma Pharmaceuticals, Inc. (SNOA) | $5.79M | -12.50% | -23.99% | -28.13% | -27.65% |
| Lucyd, Inc (LUCY)vs › | $5.86M | -102.86% | -76.90% | -95.53% | -184.55% |
| enVVeno Medical Corporation (NVNO)vs › | $5.70M | -69.39% | -57.20% | -55.49% | -56.22% |
| Scienture Holdings, Inc. (SCNX)vs › | $5.94M | -43.26% | -20.33% | -69.16% | -65.79% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.89M | -81.62% | -81.33% | -106.24% | -102.80% |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.89M | 83.82% | -0.56% | -31.49% | -28.41% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.58M | -54.95% | -72.19% | -72.80% | -69.14% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.59M | -68.33% | -234.58% | -196.81% | -171.01% |
| Soligenix, Inc. (SNGX)vs › | $5.34M | -97.52% | -106.09% | -92.87% | -84.52% |
| Femasys Inc. (FEMY)vs › | $6.28M | -99.97% | -120.54% | -89.96% | -79.52% |
ROA
-12.5%
ROE
-34.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2026-03-31 | -22.74% |
| 2025-03-31 | -25.25% |
| 2024-03-31 | -32.80% |
| 2023-03-31 | -31.74% |
| 2022-03-31 | -26.99% |
| 2021-03-31 | -26.36% |
| 2020-03-31 | -22.72% |
| 2019-03-31 | -81.66% |
| 2018-03-31 | -74.60% |
| 2017-03-31 | 36.43% |
| 2016-03-31 | -73.62% |
| 2015-03-31 | -54.51% |
| 2014-03-31 | 17.96% |
| 2013-03-31 | -43.22% |
| 2012-03-31 | -93.51% |
| 2011-03-31 | -91.74% |
| 2010-03-31 | -80.56% |
| 2009-03-31 | -324.14% |
| 2008-03-31 | -86.14% |
| 2007-03-31 | -73.41% |
| 2006-03-31 | -182.04% |
| 2005-03-31 | -238.18% |
| 2004-03-31 | 0.00% |
| 2003-03-31 | -165.97% |
| 2002-03-31 | -9.90% |
